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Marijuana or the products from the plant Cannabis sativa have 
been used both as a recreational drug and for the treatment of 
various diseases for thousands of years.[1] In South Africa (SA) the 
local Khoisan used it before the arrival of European settlers.[2] This 
use continued until the law criminalised it in 1922. Recently the 
Constitutional Court overturned the law by declaring the products 
of cannabis legal for private use.[3] In spite of previous legislation, the 
South African Medical Research Council estimated that in the year 
2008 there were ~3.2 million users of marijuana in SA.[4] At that stage 
the country was regarded as the fourth-biggest producer of marijuana 
in the world.[4]
Not all users of cannabis products use them for recreational 
purposes – many are in fact self-medicating. The recent changes in 
legislation in SA have probably led to an increase in self-medication, 
but very little official information is available on the magnitude of 
this increase. Media interest indicates that it could be significant. 
Medical professionals are often not told that their patients are using 
these products, and they are not always aware of their possible 
benefits or adverse effects. Some patients may approach their doctor 
for assistance and information. Cannabis compounds are used for a 
variety of conditions, including pain, cancer, insomnia, inflammatory 
disease and epilepsy.[5] Although scientists have investigated the 
therapeutic value of cannabis in many of these conditions, the results 
are often inconclusive and more work is needed. In some conditions, 
such as epilepsy, there is evidence that patients can benefit from using 
cannabidiol (CBD) extracted from cannabis, and this information 
could assist general practitioners in advising patients on the efficacy 
of these compounds.
Objectives
The objective of this review is to summarise the currently available 
information on the therapeutic effects of CBD, one of the main 
components of cannabis, in the treatment of epilepsy and to explore 
recent information on the mechanisms involved in these effects.
Methods
Several searches were done on PubMed (https://www.ncbi.nlm.nih.
gov/pubmed/) during the period June/July 2019. The key words 
‘epilepsy’, ‘clinical studies’, ‘therapeutic use’, ‘adverse effects’ and ‘drug 
interactions’ were used in combination with ‘cannabis’, ‘cannabinoids’ 
and ‘cannabidiol’. The abstracts were studied and the full text of 
articles of interest was acquired. Information from articles where it 
was not possible to get the full text was not included in the review.
Literature review
The family Cannabaceae consists of three species, namely C. sativa, 
C. indica and C. ruderalis.[5,6] Owing to hybridisation, it is often diffi-
cult to distinguish between the different species. C. sativa is mostly 
known for its recreational use, whereas C. indica, commonly known 
as hemp, has been cultivated over the years for its fibres, which are 
used in the manufacturing of fabrics.[5-7] This plant family contains 
more than 460 different chemicals, of which over 100 are classified 
as cannabinoids.[1] The chemical composition of the different species 
is different, especially with regard to the two major components, 
tetrahydrocannabinol (THC) and CBD. Their proportions differ in 
the different species, with THC being higher in C. sativa and CBD 
higher in C. indica.[5] One source quotes the ratio of CBD/THC in 
C. indica as 30:1.[8] These proportions may vary depending on many 
external factors the plants are exposed to, such as temperature, 
climate, time of harvesting and storage.[6]
Owing to past use and a continuous stream of anecdotal reports 
suggesting possible therapeutic advantages that can be obtained from 
using the cannabinoids, combined with the fact that more countries 
are moving towards lifting legislation prohibiting use, scientific 
interest in these compounds has shown a dramatic increase in the 
past decade.[6]
The endocannabinoid system
The search for receptors for the cannabinoids led to the discovery 
not only of the receptors but also of the endocannabinoid system 
(ECS) and the compounds N-arachidonoylethanolamide, also known 
as anandamide, N-oleoylethanolamide, N-palmatoylethanolamide, 
N-arachidonoyldopamine and 2-arachidonoyl glycerol (2-AG), 
which act as the chemical messengers of the ECS.[9,10] Of these 
compounds, anandamide and 2-AG have been extensively studied 
and are regarded by some as the physiologically most important 
of the endocannabinoids.[5,6,10] Although a lot of work still needs 
to be done on the ECS, it is speculated that it regulates various 
physiological processes including mood, pain perception, appetite 
and some cognitive functions.[11] It is also proposed that this system 
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is activated by the same factors that cause release of the endogenous 
opioids, such as stress and exercise.[12] The suggestion is that these 
different endogenous systems co-ordinate to form a modulating 
system that mediates the responses of the body’s control systems to 
different types of stress.[12]
The main targets of the endocannabinoids seem to be the 
G-protein-coupled CB1 and CB2 receptors, although there is evidence 
that many other receptors are involved in the actions of these 
compounds.[6] The receptors are found in the central nervous system 
and on some peripheral nerves and also outside the nervous system 
on many different blood cells such as the B cells, natural killer cells, 
monocytes and neutrophils, as well as CD4 and CD8 T cells.[7] The 
expression of the CB1 and CB2 receptors in the central nervous system 
is very different.[13] CB1 receptors are found in high numbers in the 
neocortex, basal nuclei, hippocampus and amygdala in the brain, as 
well as on interneurons in the dorsal horn of the spinal cord.[7] The 
CB2 receptors in the central nervous system are mainly found on the 
microglia, although there is evidence of CB2 receptors in primary 
afferents involved in pain pathways.[14] Although CB1 receptors are 
found on the immune cells, their numbers on the T cells are lower 
than those of the other immune cells mentioned above. CB2 receptors 
are also well expressed on the same blood cells as the CB1 receptors, 
again with lower numbers on the T cells.[7] The physiological 
role of the endocannabinoids in the activities of the blood cells 
involves the modulation of inflammation.[7] Activation of the CB2 
receptors inhibits the production of the cytokines tumour necrosis 
factor (TNF)-alpha, interleukin (IL)-6 and IL-8 by monocytes 
and macrophages and TNF-alpha, IL-2 and interferon (IFN)-γ 
by T  cells. [7] All these are pro-inflammatory cytokines.[7] There is, 
however, evidence that both types of receptors are present on other 
tissues in the body such as muscle, skin, bone and liver.[9,10]
Phytocannabinoids
The two main components of cannabis are THC and CBD, but 
although cannabidavarin (CBDV) and cannabinol (CBN) are 
present in lower concentrations, they are known to have neuroactive 
properties.[5,6,15] THC is well known for its psychoactive properties, 
which are also associated with adverse effects such as dizziness, 
nausea, drowsiness, mood disorders and psychosis.[5] Because of these 
adverse effects, THC is the least favoured compound of cannabis 
for possible therapeutic use.[5,6,12] For unknown reasons, CBDV and 
CBN have also not received a lot of attention from researchers, and 
little literature on the effects of these two compounds is available. [15] 
CBD, on the other hand, is well tolerated even at relatively high 
doses (studies have reported doses of 10 - 600 mg/d)[6,11,16,17] and 
has therefore received much attention. Although it has been well 
tolerated by most participants, adverse effects such as loss of appetite, 
somnolence, some gastrointestinal disturbances and nausea have 
been reported in some studies, often to the extent that participants 
had to withdraw.[6,8,17] Although CBD has few or no adverse effects in 
the majority of patients, it is important to note that no information 
is available on its possible long-term effects on the nervous system, 
especially on the developing brain.[6,18] The shorter- to medium-term 
effects of CBD on various aspects of the normal physiology have 
been studied extensively in the past few years, as well as its potential 
therapeutic use in a variety of conditions.[5,6,19] Therapeutic use has 
included its antiemetic and appetite-stimulatory effects and a possible 
role in the treatment of anxiety, depression, some types of cancer, 
Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, glaucoma, 
chronic and neuropathic pain, inflammation and epilepsy.[5,6,7,19-21] 
It is clear from the literature that the actions of the cannabinoids 
are complex and involve not only neuronal targets but also targets 
outside the nervous system.[13] The presence of receptors on blood 
cells and their role in the manipulation of the inflammatory response 
has the potential for interesting therapeutic interventions, but lies 
outside the scope of this review.
Cannabinoids can be administered topically, orally, sublingually or 
by inhalation; of these, smoking is the best known.[9,19] THC mainly 
targets the CB1 and CB2 receptors but has been found also to be an 
agonist for various receptors such as transient receptor potential 
ankyrin type 1 (TRPA1), transient potential vanilloid receptor 
types 1 (TRPV1) and 2 (TRPV2), G-protein-coupled receptor 18 
(GPR18) and GPR55.[6,13,20] CBD, on the other hand, does not have 
a high affinity for the CB1/CB2 receptors, but in high concentrations 
acts as an antagonist for CB1 and as an inverse agonist for CB2.[6] In 
animal models, CBD has been confirmed as an agonist for many 
other receptors such as TRPV1-4, TRPA, alpha-1 and alpha-3 glycine 
receptors and 5-hydroxytryptamine subtype 1a receptors, and as 
an antagonist for transient receptor melastatin type 8.[9,13,17] One of 
the more prominent ones seems to be the GPR55 receptor, which 
has been suggested to be a cannabinoid receptor, but this point is 
still controversial.[9,20,22] In a study on Parkinson’s disease, CBD was 
found to be an inverse agonist for GPR3, GPR6 and GPR12 and was 
of therapeutic significance in this condition.[20] It is also known to 
modulate adenosine A1 and A2 receptors.[23,24]
The therapeutic possibilities of the phytocannabinoids have been 
investigated in both animal and clinical studies, leading to the 
development of various synthetic cannabinoids of which some have 
been registered as medications (such as dronabinol, levonantradol 
and nabilone, which are derivatives of THC).[13,21] Others, such as 
nabiximols and Sativex, contain both THC and CBD, whereas 
Epidiolex contains only synthetic CBD.[13,19,21] None of these drugs 
are registered in SA. Interestingly, studies have shown that the herbal 
cannabinoids were four times more potent than the synthetically 
prepared products or purified CBD,[8] which seems to suggest 
a synergistic contribution from other compounds in the herbal 
preparations.[8]
Although encouraging results have been found in the therapeutic 
use of cannabinoids for various conditions in animal studies, there 
were initially few clinical studies that reproduced these benefits. 
In the earlier studies, results were compromised by small patient 
numbers and complicating factors such as experimental designs that 
left them open to criticism.[9,19,25,26] Epilepsy was chosen as the focus 
of the present review because there appear to be more reproducible 
studies in terms of therapeutic CBD benefits in this condition 
than in others. I therefore looked at the available data from studies 
investigating the therapeutic potential of CBD in the treatment of 
epilepsy and explored the mechanisms behind these possible benefits.
Epilepsy
Approximately 1% of the world’s population suffers from epilepsy, 
and it is estimated that 20 - 30% of sufferers do not achieve 
seizure control with conventional pharmacotherapies.[27-29] Various 
anecdotal reports have indicated that some of these individuals have 
benefited from using CBD. These reports ranged from cases in which 
seizures were reduced to others that reported complete cessation of 
seizures,[8,13,18] and they have elicited and increased scientific explor-
ation of the possible therapeutic properties of CBD in recent years.[8]
Initial research focused on animal models of epilepsy, and 
CBD was shown to have anticonvulsant properties in several of 
these models. [18,25] In some reports, the beneficial effects of CBD 
were enhanced by co-administration of conventional antiepileptic 
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drugs. [18,25] Animal studies were followed by several clinical studies, 
and the role of co-administration of conventional drugs with CBD 
became very relevant in the evaluation of the results because for 
ethical reasons the study participants could not be required to 
discontinue their conventional therapies while receiving CBD.[15] For 
this reason, clinical studies on patients receiving only CBD are limited.
The results from the first clinical studies were therefore treated 
with caution, as sceptics were quick to point out the possible 
contribution of the drugs co-administered with the CBD.[13] The 
fact that often the results were not from randomised, double-blind, 
placebo-controlled trials also left a question mark over the benefits 
of CBD.[6,18] However, in spite of criticism these early studies already 
suggested that CBD treatment was advantageous to patients who 
did not respond to conventional anticonvulsive therapy. Devinsky 
et al.[30] showed a 30% reduction in motor seizures in 12 weeks of 
treatment in such patients. Subsequent studies comprising cohorts of 
different age groups ranging from infants to adults also supported the 
anticonvulsant properties of CBD.[8]
Although some of these studies had relatively big sample sizes and 
the results were supported by statistics, reviewers were still critical 
of their validity because of experimental designs that were deemed 
to detract from the value of the observations. These concerns were, 
however, subsequently addressed when the benefits of CBD were 
confirmed by well-controlled randomised trials for both Lennox-
Gastaut and Dravet syndromes.[31-34] These beneficial effects of 
CBD were further confirmed by many other clinical studies that 
followed, and also by meta-analytical reviews of the published data 
on different types of epilepsy in patients of various ages ranging from 
babies to adults.[8,17,31-34] Benefits included a >50% (in some reports 
80%) decrease in the seizure rate, and some patients experienced a 
complete cessation of seizures.[17] However, it is necessary to mention 
that in many of these studies some participants withdrew because 
of adverse effects, once again highlighting the important role of the 
genetic make-up of individuals in determining how they respond to 
these compounds.[6,17]
Genetic variability was one of the complicating factors in 
interpreting the data from the earlier studies. Various studies have 
reported large inter-individual variability in reaction to the action of 
CBD.[6,15,35] This variability was highlighted in a study of CBD on pain 
perception in which some participants reported significant analgesia, 
others were not affected at all, and others reported experiencing 
hyperalgesia.[10] Another factor that complicated interpretation of 
the results was the contribution of the placebo effect. Because of 
the interest around cannabis, it was found that participants had 
extremely high expectations, and Pamplona et al.[8] refer to studies 
that recorded placebo effects as high as 40%, although they also state 
that in epilepsy studies a placebo effect of 15 - 25% is common. Such 
high percentages for placebo have a major effect on statistical analysis 
and the significance of recorded observations for the experimental 
groups. In spite of these factors, evidence that the majority of subjects 
in clinical trials benefit from the treatment of epilepsy with CBD is 
overwhelming.
Mechanism of action
In view of the above, it is important to investigate the mechanisms 
responsible for the anticonvulsant therapeutic benefits of CBD. A 
great deal of information on the mechanism of the anticonvulsive 
actions of CBD has become available in recent years. These 
mechanisms can be divided into those that involve manipulation of 
the ECS and those that are more direct. The ECS plays an important 
role in the control of synaptic transmission and through this regulates 
the excitability of neuronal networks in the nervous system.[12] 
CB receptors are expressed presynaptically on glutamatergic and 
GABAergic interneurons and can thereby modulate the release of 
their neurotransmitters.[6] The ECS is generally regarded as being 
anticonvulsive by preventing hyperexcitability, and deficiencies in 
this system have been linked to the pathophysiology of certain types 
of epilepsy.[25,36-39]
Although we know that CBD has a low affinity for the CB1/
CB2 receptors, it can therefore indirectly modulate these receptors 
by enhancing the actions of the ECS.[13] It does so via various 
mechanisms, the first of which is to prolong the effect of anandamide 
by inhibition of its reuptake.[10,20] Secondly, it inhibits amide hydrolase, 
5-lipoxygenase and fatty acid amide hydrolyze, the enzymes 
responsible for the degradation of the endocannabinoids.[7,10,13,20]
Most conventional antiepileptic drugs act to reduce 
neuronal excitability by either blocking the release of excitatory 
neurotransmitters such as glutamate or by enhancing the release of 
inhibitory neurotransmitters such as GABA.[17] The evidence is that 
antiepileptic drugs also target voltage-gated ion channels.[17] This 
mechanism involves the targeting of specific ion channels, namely 
the Na+ and Ca2+ channels, where some drugs would target either one 
of the two and others actually target both.[22] Indications are that the 
more direct effects of the endocannabinoids may also employ these 
mechanisms. Although CBD has a low affinity for the CBD receptors, 
it has a high affinity for binding to the TRPV receptors, among 
others.[17] Activation of the TRPV receptors normally increases the 
Ca2+ permeability of neuronal membranes, resulting in the increased 
release of glutamate. Through the interaction of CBD with the TRPV 
receptors, these receptors are desensitised and the intracellular 
Ca2+ is normalised, thereby preventing the release of glutamate. [17] 
The inhibition of glutamate release is a well-known occurrence 
that results from CB1 receptor stimulation, but since CBD does not 
stimulate these receptors directly, the effect would be an indirect 
one by enhancing the ECS, as CBD downregulates fatty acid amide 
hydrolase and 5-lipoxygenase enzymes to increase anandamide 
levels.[20,40] CBD has also been shown to block T-type Ca2+ channels 
that normally increase the excitability of neurons.[17] Abnormalities in 
the activation of these channels have also been implicated as involved 
in some types of epilepsy.[41]
Other channels that have been implicated as involved in epilepsy 
are the 5-hydroxytryptamine (HT) receptors.[6,13,17,20] They form part 
of a group of G-protein-coupled receptors that can be subdivided into 
seven different classes (5-HT1-7).[17] These are serotonin receptors, and 
although they are thought to be involved in the aetiology of epilepsy, 
the exact mechanisms are not currently clear.[6,7,11,17] It is, however, 
known that CBD has a high affinity for the two subtypes 5-HT1A 
and 5-HT2A, and the suggestion is that some of the anticonvulsive 
effects of CBD can be attributed to its action via these receptors.[17] 
Similarly, the opioid receptors (ORs) have been implicated in the 
aetiology of epilepsy, and they have also been linked to CBD.[14,17,21] 
The ORs are incidentally also G-protein-coupled receptors, and the 
anticonvulsive effects of CBD are linked to the fact that they block the 
mu- and delta-ORs.[17] Although it is outside the scope of this review, 
I would like to note that these receptors also make for some exciting 
prospects in the therapeutic use of CBD for the treatment of pain in 
conjunction with current opioid therapies.[14]
The exact physiological roles of another G-protein-coupled 
receptor, GPR55, are still controversial, but there is evidence that 
CBD acts as an antagonist for these receptors and it is suggested 
that this antagonism also contributes to the anticonvulsive effects of 
CBD.[6,7,20] Normally GPR55 stimulation leads to intracellular Ca2+ 
mobilisation and a subsequent glutamate release that is abolished by 
the CBD binding to these receptors.[20]
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The last mechanism to consider is one involving adenosine. 
Evi dence in the literature points to the fact that CBD inhibits 
the reuptake of adenosine.[6,7,42-44] Adenosine normally acts as a 
neuroprotective agent in the central nervous system, and its levels 
usually increase under conditions of stress. Earlier I alluded to the 
fact that the ECS plays a role in modulating the nervous system 
responses to stress. The fact that CBD administration assists in 
increasing adenosine levels in the nervous system would support 
such a mechanism. Adenosine action via the adenosine A1 receptors 
opens K+ channels to hyperpolarise neurons and thereby reduce their 
excitability, which would be an obvious advantage in epilepsy.[43] Via 
the same receptor, adenosine can also inhibit the N-type voltage-
gated Ca2+ channel to inhibit the release of glutamate, which normally 
increases the excitability of neuronal networks.[44]
Conclusions
The therapeutic benefit of CBD administration in the treatment 
of epilepsy has been established without doubt in other countries. 
It is, however, important to understand that owing to genetic 
variability there are some patients who do not receive benefit 
from this treatment. This is particularly important in SA, which 
has a population that represents a large genetic diversity. There is 
therefore a great need for clinical trials in SA involving patients who 
represent the diversity of the country and are not responding well 
to currently available drugs in order to establish how these patients 
could best benefit from this new therapeutic approach. It is also 
important to note that herbal preparations from cannabis plants can 
be of inconsistent quality, mainly because these plants are cultivated 
under a variety of conditions. As cannabis products are currently 
very topical and are becoming more readily available in SA, medical 
professionals need to increase their knowledge about the possible 
therapeutic benefits and adverse effects of the various compounds 
obtained from these plants.
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